Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is projected to announce its Q4 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($1.52) per share and revenue of $61.18 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The firm had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company’s revenue was up 171.0% compared to the same quarter last year. During the same period last year, the company earned ($1.26) EPS. On average, analysts expect Arrowhead Pharmaceuticals to post ($3.62) EPS for the current fiscal year and ($4.73) EPS for the next fiscal year.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $61.65 on Thursday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company has a 50 day moving average of $68.15 and a 200-day moving average of $71.55. Arrowhead Pharmaceuticals has a twelve month low of $37.06 and a twelve month high of $95.49. The stock has a market capitalization of $8.68 billion, a P/E ratio of -27.40 and a beta of 1.34.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Chardan Capital restated a “buy” rating and issued a $115.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. The Goldman Sachs Group initiated coverage on Arrowhead Pharmaceuticals in a report on Thursday, September 24th. They issued a “neutral” rating and a $74.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. Citigroup assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 8th. They issued a “buy” rating and a $108.00 target price on the stock. Finally, Morgan Stanley lifted their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael Perry sold 11,600 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director directly owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.